All questionsPharmacology: Ibrance (palbociclib), all indications10 questions · 2 sourcesMechanismHow does Ibrance work (mechanism of action)?“Palbociclib is an inhibitor of cyclin-dependent kinases (CDK) 4 and 6. Cyclin D1 and CDK4/6 are downstream of signaling pathways which lead to cellular proliferation. In vitro, palbociclib reduced cellular proliferation of estrogen receptor (ER)-positive breast cancer cell lines by blocking progression of the cell from G1 into S phase of the cell cycle. Treatment of breast cancer cell lines with the combination of palbociclib and antiestrogens leads to decreased retinoblastoma (Rb) protein phosphorylation resulting in reduced E2F expression and signaling, and increased growth arrest compared to treatment with each drug alone. In vitro treatment of ER-positive breast cancer cell lines with the combination of palbociclib and antiestrogens led to increased cell senescence compared to each drug alone, which was sustained for up to 6 days following palbociclib removal and was greater if antiestrogen treatment was continued. In vivo studies using a patient-derived ER-positive breast cancer xenograft model demonstrated that the combination of palbociclib and letrozole increased the inhibition of Rb phosphorylation, downstream signaling, and tumor growth compared to each drug alone.” (opens the source at this quote in a new tab)CopyFlagDo bone marrow cells recover after Ibrance exposure ends (in vitro)?“Human bone marrow mononuclear cells treated with palbociclib in the presence or absence of an anti-estrogen in vitro did not become senescent and resumed proliferation following palbociclib withdrawal.” (opens the source at this quote in a new tab)CopyFlagPharmacokineticsHow is Ibrance metabolized?“Palbociclib is primarily metabolized by CYP3A and sulfotransferase (SULT) enzyme SULT2A1.” (opens the source at this quote in a new tab)CopyFlag“In vitro and in vivo studies indicated that palbociclib undergoes hepatic metabolism in humans. Following oral administration of a single 125 mg dose of [14C]palbociclib to humans, the primary metabolic pathways for palbociclib involved oxidation and sulfonation, with acylation and glucuronidation contributing as minor pathways. Palbociclib was the major circulating drug-derived entity in plasma (23%). The major circulating metabolite was a glucuronide conjugate of palbociclib, although it only represented 1.5% of the administered dose in the excreta. Palbociclib was extensively metabolized with unchanged drug accounting for 2.3% and 6.9% of radioactivity in feces and urine, respectively. In feces, the sulfamic acid conjugate of palbociclib was the major drug-related component, accounting for 26% of the administered dose. In vitro studies with human hepatocytes, liver cytosolic and S9 fractions, and recombinant SULT enzymes indicated that CYP3A and SULT2A1 are mainly involved in the metabolism of palbociclib.” (opens the source at this quote in a new tab)CopyFlagWhat is the half-life of Ibrance?“The geometric mean apparent oral clearance (CL/F) of palbociclib was 63.1 L/hr (29% CV), and the mean (± standard deviation) plasma elimination half-life was 29 (±5) hours in patients with advanced breast cancer.” (opens the source at this quote in a new tab)CopyFlag“Steady state was achieved within 8 days following repeated once daily dosing.” (opens the source at this quote in a new tab)CopyFlagWhat is the protein binding of Ibrance?“Binding of palbociclib to human plasma proteins in vitro was approximately 85%, with no concentration dependence over the concentration range of 500 ng/mL to 5000 ng/mL. The mean fraction unbound (fu) of palbociclib in human plasma in vivo increased incrementally with worsening hepatic function. There was no obvious trend in the mean palbociclib fu in human plasma in vivo with worsening renal function. The geometric mean apparent volume of distribution (Vz/F) was 2583 L with a coefficient of variation (CV) of 26%.” (opens the source at this quote in a new tab)CopyFlagHow is Ibrance excreted from the body?“In 6 healthy male subjects given a single oral dose of [14C] palbociclib, a median of 91.6% of the total administered radioactive dose was recovered in 15 days; feces (74.1% of dose) was the major route of excretion, with 17.5% of the dose recovered in urine. The majority of the material was excreted as metabolites.” (opens the source at this quote in a new tab)CopyFlagHow quickly do Ibrance tablets and capsules reach peak blood levels?“The maximum observed concentration (Cmax) of palbociclib is generally observed between 4 to 12 hours (time to reach maximum concentration, Tmax) following oral administration of IBRANCE tablets.” (opens the source at this quote in a new tab)CopyFlag“The mean maximum observed concentration (Cmax) of palbociclib is generally observed between 6 to 12 hours (time to reach maximum concentration, Tmax) following oral administration.” (opens the source at this quote in a new tab)CopyFlag“The mean absolute bioavailability of IBRANCE after an oral 125 mg dose is 46%.” (opens the source at this quote in a new tab)CopyFlagNote: The first and third passages are from the IBRANCE tablets Prescribing Information and the second from the IBRANCE capsules Prescribing Information.How does food affect absorption of Ibrance tablets?“Food Effect: The area under the concentration-time curve from zero to infinity (AUCINF) and Cmax of palbociclib increased by 22% and 26%, respectively, when IBRANCE tablets were given with a high-fat, high-calorie meal (approximately 800 to 1000 calories with 150, 250, and 500 to 600 calories from protein, carbohydrate, and fat, respectively), and by 9% and 10%, respectively, when IBRANCE tablets were given with a moderate-fat, standard-calorie meal (approximately 500 to 700 calories with 75 to 105, 250 to 350 and 175 to 245 calories from protein, carbohydrate, and fat, respectively), compared to IBRANCE tablets given under overnight fasted conditions.” (opens the source at this quote in a new tab)CopyFlagComponentsWhat are the inactive ingredients in Ibrance tablets?“Inactive Ingredients: Microcrystalline cellulose, colloidal silicon dioxide, crospovidone, magnesium stearate, succinic acid, HPMC 2910/hypromellose, titanium dioxide, triacetin, and FD&C Blue #2/Indigo Carmine Aluminum Lake. In addition, the 75 mg and 125 mg tablets contain red iron oxide and the 100 mg tablets contain yellow iron oxide.” (opens the source at this quote in a new tab)CopyFlagWhat are the inactive ingredients in Ibrance capsules?“Inactive ingredients: Microcrystalline cellulose, lactose monohydrate, sodium starch glycolate, colloidal silicon dioxide, magnesium stearate, and hard gelatin capsule shells. The light orange, light orange/caramel, and caramel opaque capsule shells contain gelatin, red iron oxide, yellow iron oxide, and titanium dioxide; the printing ink contains shellac, titanium dioxide, ammonium hydroxide, propylene glycol, and simethicone.” (opens the source at this quote in a new tab)CopyFlag